Icon (ICLR) Expected to Release Quarterly Earnings on Wednesday

Icon (NASDAQ:ICLR) is anticipated to post its Q1 2026 results after the market closes on Wednesday, July 29th. Analysts expect Icon to announce earnings of $2.55 per share and revenue of $2.0043 billion for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, June 24, 2026 at 8:00 AM ET.

Icon Price Performance

Shares of ICLR opened at $165.76 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.31. The stock has a market cap of $12.69 billion, a PE ratio of 29.49, a PEG ratio of 8.14 and a beta of 1.22. Icon has a 12-month low of $66.57 and a 12-month high of $203.91. The business has a 50-day simple moving average of $151.11 and a two-hundred day simple moving average of $136.00.

Hedge Funds Weigh In On Icon

Several institutional investors have recently made changes to their positions in ICLR. EFG International AG acquired a new stake in Icon in the fourth quarter valued at approximately $27,000. Johnson Financial Group Inc. bought a new position in shares of Icon in the 3rd quarter worth $71,000. Quadrant Capital Group LLC bought a new position in shares of Icon in the 3rd quarter worth $78,000. Geneos Wealth Management Inc. grew its position in Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its stake in Icon by 198.8% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 487 shares of the medical research company’s stock valued at $89,000 after purchasing an additional 324 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. BMO Capital Markets upped their price objective on shares of Icon from $160.00 to $187.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Mizuho lifted their target price on shares of Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, June 26th. DA Davidson set a $164.00 target price on shares of Icon in a report on Monday, June 1st. Robert W. Baird upped their price target on shares of Icon from $168.00 to $186.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Finally, Barclays increased their price target on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday, June 25th. Seven equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Icon presently has a consensus rating of “Hold” and a consensus price target of $168.73.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.